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Background: Oval cells, specific liver progenitors, are activated in response to injury. The human umbilical
cord blood (hUCB) is a possible source of transplantable hepatic progenitors and can be used in cases of
severe liver injury. We detected the effect of hUCB stem cell transplantation on natural response of oval cells
to injury.
Methods: Twenty-four female albino rats were randomly divided into three groups: (A) control, (B) liver injury
with hepatocyte block, and (C) hUCB transplanted group. Hepatocyte block was performed by administration of
2-acetylaminofluorene (2-AAF) for 12 days. CCL4 was administrated at day 5 from experiment start. Animals were
sacrificed at 9 days post CCL4 administration, and samples were collected for biochemical and histopathological
analysis. Oval cell response to injury was evaluated by the percentage of oval cells in the liver tissue and frequency of
cells incorporated into new ducts.
Results: Immunohistochemical analysis of oval cell response to injury was performed. There was significant deviation
in the hUCB-transplanted (4.9 ± 1.4) and liver injury groups (2.4 ± 0.9) as compared to control (0.89 ± 0.4) 9 days post
injury. Detection of oval cell response was dependant on OV-6 immunoreactivity. For mere localization of cells with
human origin, CD34 antihuman immunoreactivity was performed. There was no significant difference in endogenous
OV-6 immunoreactivity following stem cell transplantation as compared to the liver injury group.
Conclusions: In vivo transplantation of cord blood stem cells (hUCB) does not interfere with natural oval cell response
to liver injury.
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Liver stem cell participation in recovery of the severely
injured liver have been extensively described. Nevertheless,
the exact location of such stem cells is still controversial
although bile ducts have been implicated [1]. In experi-
mental carcinogenesis proliferation of the so-called oval
cells has been described. These cells are small with oval
nuclei that reside in the periphery of the portal tracts in rat
models of hepatocarcinogenesis and injury. Oval cells are* Correspondence: hussein.abdullatif@hotmail.com
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hepatocytes and cholangiocytes [2]. Their precise nature
remains unclear with debate as to whether they are derived
from a postulated stem cell or are themselves facultative
stem cells. An enormous range of markers has been used
for oval cell identification, such as albumin, alpha fetal pro-
tein (AFP), epithelial cell adhesion molecule (EpCAM),
cytokeratin 7 (CK7), OV-6, and cytokeratin 19 (CK19)
[3, 4]. Human umbilical cord blood may be a possible
source of transplantable hepatic progenitors. Newsome
and his colleagues demonstrated that human umbilical
cord blood (hUCB) stem cells could differentiate into
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with hematopoietic cells (c-kit, flt-3, CD34) can be
expressed by oval cells/hepatic progenitor cells (HPCs)
as well, leading to the notion that at least some hepatic
oval cells are directly derived from a precursor of
hematopoietic origin [6]. The underlying mechanism of
stem cell plasticity and transdifferentiation into mature
hepatocytes is of considerable interest. Exploring the
therapeutic potential and role of oval cells in the
process of natural repair of the liver is of great value
and carries much hope in the future for the treatment
of liver disease. Studying cord blood stem cells as a
source of transplantable liver progenitors, and whether
this may interfere with the natural response of oval
cells to injury, to our knowledge is still unclear. Thus
the aim of the current work was directed to study the
effect of hUCB stem cell transplantation on the natural
response of oval cells to liver injury.
Methods
Collection of human umbilical cord blood
Human umbilical cord blood was collected from full-
term pregnant women (Department of Obstetrics and
Gynecology, Mansoura University) just before placental
separation in normal vaginal delivery after taking inform-
ative consent. Participants were considered eligible for the
study according to the following exclusion (no family
history of gene-based disorders or maternal fever during
labor) and inclusion (delivery occurring less than 24 h
after rupture of membranes) criteria.
Separation of the mononuclear cells
Human umbilical cord blood samples were diluted in
Dulbecco’s modified Eagle’s medium (DMEM) (1:1)
supplemented with 10% fetal bovine serum (FBS). Low-
density mononuclear cells were collected after centrifu-
gation at 800×g for 20 min in Ficoll density gradient
(Histopaque, 1.077 g ml−1) following the manufacturer’s in-
structions. Mononuclear hematopoietic cells were obtained
from the interphase and washed twice with sterilized PBS.
Pellets were re-suspended in lysis buffer (150 mM NH4 Cl,
1 mM KHCO3, 0.1 mM Na-EDTA, pH 7.4) and incubated
for 5 min at 4 °C to deplete erythrocytes. After washing
once with PBS, pellets were again re-suspended. Cell
viability, determined by the trypan blue dye exclusion
method, was 97.40 ± 0.43%. The total average number of vi-
able cells isolated from one umbilical cord was 8 × 107 [7].
Animal preparation
Twenty-four adult female albino rats (Cux1: HEL1)
12 weeks of age, weighing 200–250 g. Rats were bred
and maintained in an air-conditioned animal house
(Medical Experimental Research Center, MERC, Mansoura
University) (under controlled temperature 25 ± 2 °C) withspecific pathogen-free environment and were subjected
to a 12:12-h daylight/darkness cycle and allowed free
access to rat chow and water. The principles of labora-
tory animal care were fulfilled in all experimental pro-
tocols and were approved by the ethics committee of
animal research in MERC.Animal groups
Rats were randomly divided into the following groups:
 Control group (n = 8). The rats received corn
oil (10 ml kg−1 B.W.) orally throughout the
whole experiment.
 Liver injury and hepatocyte block group (n = 8).
The rats received acetylaminofluorene (2-AAF)
(A7015, Sigma-Aldrich) to inhibit hepatocyte
proliferation. The drug was administered in a dose
of (10 mg kg−1 B.W.) as daily oral gavage for 12 days.
2-AAF was dissolved in a small volume of dimethyl
sulfoxide (DMSO; Sigma cat: D8418) and suspended
in corn oil to a final concentration of 2 mg ml−1.
On day 5 from the start of the experiment, rats
received carbon tetrachloride (CCL4) in a dose of
0.6 ml kg−1 B.W. dissolved in corn oil (1:1) to
induce differentiation of oval cells.
 Stem cell transplantation group (n = 8). The rats
were subjected to 2-AAF/CCL4 liver injury
protocol as described before; in addition, they
also received human umbilical cord blood stem
cells (mononuclear cells, MNCs) as a source of
exogenous stem cells to the liver. This group
received hUCB MNCs (8 × 106) in 0.3 ml media
injection (DMEM) over 3 min through the portal
vein on the day following CCL4 administration.
Rats in different groups were sacrificed at day
9 post CCL4 injury.
Biochemical analysis
Heparinized blood samples were obtained from all ani-
mals at planned time intervals. Aspartate transaminase
(AST) and alanine transaminase (ALT) activities and serum
albumin and total bilirubin levels in the plasma were deter-
mined using commercially available kits (Sigma Chemical
Co. kit nos. 58 and 59).Specimens’ collection
The livers were harvested following in situ perfusion
through the portal vein using Ca++-free Hank’s balanced
salt solution (HBSS) (pH 7.4). The initial flow rate was
15–20 ml min−1 with the perfusate exiting through the
inferior vena cava. The livers were divided into pieces
and were used for histopathological studies.
Table 1 Plasma levels of ALT, AST, albumin, and bilirubin in rats
Group A control Group B liver
injury group
Group C (2AAF/CCL4 +
stem cell transplantation)
At 9 days post CCL4 injury
ALT 42.6 ± 2.8 114 ± 37.5* 132.8 ± 21.1*
AST 44.3 ± 3.5 265 ± 187.3* 162.5 ± 34.8*
Albumin 3.9 ± 0.3 3.9 ± 0.2 3.95 ± 0.13
Bilirubin 0.31 ± 0.18 0.31 ± 0.16 0.28 ± 0.11
Values are expressed as means ± SD
*Significant deviation from the control group as indicated by P < 0.05
Abdellatif et al. Inflammation and Regeneration  (2017) 37:5 Page 3 of 8Staining
Small pieces of liver were collected and fixed overnight
in 10% neutral-buffered formalin. The fixed liver tissue
was then dehydrated in ascending grades of alcohol and
then cleaned by xylene then embedded in paraffin. Five-
micrometer-thick sections were mounted on clean glass
slides. Sections were stained with hematoxylin-eosin
(HE) for histopathological changes, antihuman/rat OV-
6 antibody (R&D Systems, MAB2020) for the detection
of oval cells that may originate from human or rat
source, and antihuman CD34 monoclonal antibody
(Thermo Scientific, MAI-21937) directed only for the
detection of cells that originate from a human source
(hUCB-derived cells).
OV-6 and CD34 immunohistochemistry
Tissue sections were rehydrated in decreasing concen-
trations of ethanol, and endogenous peroxidase activity
was blocked with 0.5% hydrogen peroxide in methanol.
The tissue was microwaved to boiling for 20 min in
0.1 mol l−1 of Tris EDTA pH 9.0 for antigen retrieval.
The antibody was diluted in phosphate-buffered saline
plus 0.1% nonfat dried milk and applied at 4 °C for 12 h.
Primary antibody dilution was 1:10 for OV-6 and 1:80 for
CD34. The tissue was incubated with biotinylated anti-
mouse secondary antibody in a species-specific manner
(R&D Systems, MAB002). The label was peroxidase-
conjugated streptavidin. Color development was per-
formed with diaminobenzidine peroxidase substrate
(D-4293, Sigma Chemical Co.). Finally, sections were
counterstained for 2 min with hematoxylin, dehydrated
through graded alcohols, and mounted under glass
cover slips.
Image analysis
Analysis of oval cell response was done using an Olympus
microscope at a total magnification of 400, captured by
digital camera (Olympus LC20) and using the image
analyzer software (LC micron). The image analyzer was
calibrated at first to convert the measurement units
(pixels) produced by the image analyzer program into ac-
tual micrometer units. Oval cells were quantified by
counting cells positive for OV-6 antigen, relative to total
hepatocyte numbers, in 10–15 randomly selected fields of
the portal tracts in a blinded way at 400× magnification.
The cell count is then expressed as a percentage in rela-
tion to the hepatocyte number.
The oval cell response and the frequency of oval cell
incorporation into new ducts were scored as (1) oval
cells constituting 10% of the field and only 10% of oval
cells were incorporated into new ducts, (2) oval cells
constituting 20% of the field and only 20% of oval cells
were incorporated into new ducts, (3) oval cells consti-
tuting 30% of the field and 30% of oval cells wereincorporated into new ducts, (4) oval cells constituting
40% of the field and 40% of oval cells were incorporated
into new ducts, and (5) oval cells constituting 50% of the
field and 50% of oval cells were incorporated into new
ducts. Average cell percentages were then pooled for
each experimental group, and the overall mean and
standard deviation were determined, and then the over-
all response was scored according to the previously de-
scribed score.
Statistical analysis
As the oval cell reaction is not uniform around all the
portal tracts over their complete size range and the reac-
tion varies between different animals at different time
intervals, the coefficient of variation (CV) was calculated
and it was statistically significant for all groups. Data are
expressed as mean ± SD. Multiple comparisons were
done using SPSS 15.0 computer software. Significance of
results was considered at P value <0.05.
Results
Biochemical analysis
Nine days post CCL4 injection, ALT and AST levels
were estimated in the blood of all experimental groups
and were significantly elevated in the liver injury (114 ±
37.5, 265 ± 127.3) and stem cell transplantation groups
(132.8 ± 21.1, 162.5 ± 34.8) as compared to the control
group (42.6 ± 2.8, 44.3 ± 3.5), respectively. Data are
expressed as mean ± SD. Pairwise comparison between
sample means reveals significant difference between
groups. Data are considered significant at P value <0.05.
Serum albumin and bilirubin levels were also estimated
in all groups, and no significant difference was found in
the liver injury (3.9 ± 0.2, 0.31 ± 0.16) or stem cell trans-
plantation group (3.95 ± 0.13, 0.28 ± 0.11) as compared
to the control (3.9 ± 0.3, 0.31 ± 0.18), respectively, as in-
dicated by P value >0.05 (Table 1).
Changes in oval cell response in hematoxylin and eosin
stained liver sections
No evidence of oval cells was observed in the control
group (Fig. 1a). In the 2-AAF/CCL4 group, oval cells
Fig. 1 Photomicrograph of liver tissue in the control (a), liver injury (b), and stem cell transplantation groups (c). a Normal liver architecture, some
hepatocytes, are binucleated (arrows). No signs of oval cell response around the portal vein (PV). b Oval cell response with ductular reaction
(arrows) and small hepatocyte-like cells (short arrows). c Increased oval cell response (arrows) with ductular reaction (D) around portal vein (PV).
Small hepatocyte-like cells (arrowheads). Inset: high magnification showing oval cells (arrowhead) with scanty basophilic cytoplasm (arrow) and
high nucleo-cytoplasmic ratio (b, c). H&E, 100×; Inset, 400×
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files between hepatocytes in the periportal regions or
extending beyond the periportal region. These cells
had scanty basophilic cytoplasm, dark staining nucleus
with a large nucleo-cytoplasmic ratio (Fig. 1, inset).
The cells radiate from the periportal region in the
form of individual cells or ductular-like structures
(Fig. 1b, arrowheads). Some cells also appeared as in-
dividual oval-shaped cells with hepatocyte phenotype
(small hepatocyte-like cells) (Fig. 1b, short arrows). In
the stem cell transplantation group, there was evident
increase in oval cells surrounding the portal tract or
emanating from it and invading the liver parenchyma
extending far beyond the periportal region (Fig. 1c,
arrows). Pairwise comparison between groups reveals
a highly significant result in the stem cell transplant-
ation group (4.8 ± 1.5, 4.5 ± 1.4) than in the liver in-
jury (3.5 ± 1.4, 3.3 ± 1.5) and control groups regarding
oval cell score and duct formation score, respectively
(P value <0.05).Changes in oval cell response detected by
immunoreactivity (IHC methods)
In the control group, mild immunoreactivity to OV-6
antibody was only limited to the intraportal bile duct
and terminal duct cells located at the Canals of Hering
(Fig. 2d, arrows). No CD34 positive cells were present in
the stained liver samples (no cross-reactivity or evidence
of human-derived cells). Oval cell response was 0.85 ±
0.4 and 0.78 ± 0.3 regarding the oval cell score and duct
formation score, respectively. In the liver injury and hep-
atocyte block group, marked increase in OV-6 immuno-
reactivity (2.4 ± 0.9, 2.3 ± 0.8) was observed (Fig. 2e,
arrows). No CD34 immunoreactivity was detected. In
stem cell transplantation group, significant increase in
OV-6 immunoreactivity was observed (4.9 ± 1.4, 4.8 ± 1.2)
(Fig. 3) with oval cells forming more reactive ductules
(ductular-like oval cells) (Fig. 2f, arrows) or appearing as
small hepatocyte-like cells. CD34 (antihuman) immunore-
activity reveals presence of positively stained cells (Fig. 2g,
arrows) which demonstrates oval cells derived from
Fig. 2 Photomicrograph of liver tissue in the control (d), liver injury (e), and stem cell transplantation groups (f, g). d Mild immunoreactivity to OV-6
antibody limited to intraportal bile duct and terminal duct cells (arrows) surrounding the portal vein (PV). e OV-6 immunoreactivity (cytoplasmic reaction)
with oval cells forming more reactive ductules (arrows) or appearing as small hepatocyte-like cells (arrowhead). The cells are surrounding the portal vein
(PV) or emanating from it and invading liver parenchyma. f Increased OV-6 immunoreactivity with oval cells forming more reactive ductules (arrows)
around the portal vein. Inset: Positive oval cells in the reactive ductules (arrow), 400×. g CD34 immunoreactivity of the human oval cells (arrows) scattered
and invading the liver parenchyma. Immunoperoxidase stain, 400×
Fig. 3 Oval cell response detected by OV-6 immunoreactivity showing highly significant increase in the stem cell transplantation group (double asterisk) as
compared to the liver injury (asterisk) and control groups (P value <0.01). Data are expressed as mean ± SD
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and frequency of exogenous cells incorporated into new
ducts were 3.2 ± 1.2 and 2.2 ± 0.9, respectively. Calculation
of the acquired data (oval cells +ve for OV-6, antihuman/
anti-rat Ab - CD34 +ve cells for antihuman Ab = oval cells
of only rat origin). No significant difference was found in
the acquired data as compared to the response observed
in the liver injury and hepatocyte block group. Previously
calculated data reveals that hUCB stem cell transplant-
ation has no effect on endogenous response of oval cells
to liver injury.
Discussion
The liver can regenerate itself by increasing the rate of
hepatocyte mitosis and stem cell differentiation into he-
patocytes or cholangiocytes. Stem cells are the principle
cell lineage for liver regeneration. However, the exact lo-
cation of these cells is not yet clear [8].
Oval cells represent the progeny of liver stem cells and
function as an amplification compartment for the gener-
ation of new hepatocytes [9]. This compartment, consisting
of small ovoid cells with scant lightly basophilic cytoplasm,
is widely used to describe liver progenitors [10]. Here,
we describe whether application of stem cells (hUCB)
interferes with the natural response of oval cells to in-
jury (represented by the percentage of oval cells in liver
tissue and the frequency of new duct formation) or not.
The general principle underlying oval cell activation is
based on a combination of liver injury with inability of
hepatocytes to proliferate in response to damage [11].
According to these data, the 2-AAF/CCL4 protocol was
used in the current work to induce an oval cell response.
CCL4 is a known chemical to induce injury in the hepatic
centri-lobular area while 2-AAF has been shown to block
proliferation of hepatocytes, thus allowing oval cells to
continue to proliferate in large numbers. Oval cells lack
the ability to convert the 2-AAF to its toxic metabolite,
thus escaping its inhibitory effect. This procedure induces
a robust response of oval cells reaching its peak 9 days
post CCL4 injury, and this was the time determined to
detect for oval cell response in our model [12].
Liver injury is followed by extensive changes in variety
of enzyme activities as part of the regenerative process
[13] (Table 1). In the current work, the ALT, AST, albu-
min, and bilirubin levels were estimated in different
groups 9 days post injury and compared to the control.
ALT and AST were significantly elevated in the liver
injury and stem cell transplantation groups (P value
<0.05). The most likely explanation for this transaminase
elevation is the release of enzymes from damaged liver
parenchymal cells. In contrast, the albumin and bilirubin
levels were not significantly different from the control
level and this was concomitant with the findings stated
by Shakoori and his associates who failed to see anyeffect on the total protein and bilirubin levels during the
first 20 days post injury [14]. The explanation for this
may be due to restoration of liver mass and function
starting the second week post injury.
In the current work, hUCB was used as a source of
hepatic progenitors and this was based on findings noted
by Newsome and his colleagues who stated that human
umbilical cord blood (hUCB)-derived cells could differen-
tiate into hepatocytes in vivo after their transplantation in
immunodeficient mice [5]. This was further modified by
Tang and his colleagues who showed that number of posi-
tive human AFP and ALB cells in the HUCBSC-treated
animals with or without cyclophosphamide did not differ
significantly, denoting that immunosuppression had either
a mild or no effect on stem cell differentiation in rats [15].
Besides, undifferentiated cells were used in the current
work, based on findings of Peters and his colleagues who
demonstrated that better results are obtained with undif-
ferentiated stem cells because these cells have very low
apoptotic activity responsible for their longer survival.
They are lowest in expressing apoptotic proteins, Asp,
annexin-V, bax, bad, and bak [16]. These cells derived
from the cord blood exhibit higher plasticity than the re-
spective mouse or rat cells [17]. Cell fusion has been im-
plicated as the mechanism by which human cells are seen
in the recipient’s liver in most cases [18].
Immunohistochemical analysis of oval cell response in
all experimental groups has been evaluated (oval cell score
and frequency of cells incorporated into new ducts) and
revealed highly significant deviation in stem cell trans-
plantation group (4.9 ± 1.4, 4.8 ± 1.2) as compared to the
liver injury (2.4 ± 0.9, 2.3 ± 0.8) and control groups (0.85 ±
0.4, 0.78 ± 0.3) (Fig. 3). OV-6 immunoreactivity was only
limited to intraportal bile ducts and terminal duct cells
with no evident induced oval cell response in the control
group. In the liver injury group, response was significantly
increased due to 2-AAF-induced mito-inhibitory effect on
liver resident hepatocytes and CCL4-induced oval cell
activation. Highly significant deviation was found in the
stem cell transplantation group, as OV-6 immunoreactiv-
ity was directed to cells of both human and rat origin
(using antihuman/rat OV-6 antibody). For mere
localization of cells with human origin, CD34 antihuman
immunoreactivity was performed. Co-staining of OV-6
and CD34 was technically not possible in liver tissue sec-
tions as both antigens are membranously expressed to the
same extent [19], and this was treated by staining for OV-
6 antigen followed by CD34 in the serial parallel liver tis-
sue section, and co-localization of both antigens was done.
Analysis of results reveals no significant change in OV-6
immunoreactivity following stem cell transplantation as
compared to the liver injury group.
The application of stem cells in liver therapies seems
to be a promising feature for treatment of liver diseases.
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fill this promise. The fundamental molecular pathways
involved in differentiation of hepatocytes and cholangio-
cytes from stem/progenitor cells need to be explored in
more details [20]. Much less is known about the mecha-
nisms of oval cell replication and differentiation [21],
and whether the natural response of oval cells to injury
is enhanced or decreased by extrahepatic sources of stem
cells (like hUCB) is not recently declared. To our know-
ledge, this is the first time to use an immunohistochemical-
based assay to prospectively detect the effect of hUCB stem
cells on the natural response of oval cells to liver injury.
Conclusions
Liver regeneration is a well-organized process by hepato-
cytes and non-parenchymal cells. Oval cells, resident liver
progenitors, play a major role in the natural response of
the liver to injury. Extrahepatic stem cells (like hUCB) have
recently been used as sources of transplantable hepatic
progenitors. In the current work, we aimed to detect the
effect of stem cell transplantation (hUCB-derived cells) on
oval cell response to injury (represented by oval cell score
and the frequency of cells incorporated into new ducts).
Based on our results, oval cell response to liver injury is
not affected by extrahepatic stem cell transplantation.
Thus, in vivo differentiation of cord blood stem cells to
liver progenitors or hepatocytes (mostly occurring by cell
fusion with resident cells) does not interfere with the
natural response of oval cells to injury. These molecular
pathways for cellular differentiation and signalling need to
be further explored.
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